Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 Aug 2021
Historique:
received: 22 07 2021
revised: 10 08 2021
accepted: 11 08 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 7 10 2021
Statut: epublish

Résumé

EGFR is overexpressed in the majority of clear cell renal cell carcinomas (CCRCCs). Although EGFR deregulation was found to be of great significance in CCRCC biology, the EGFR overexpression is not associated with EGFR-targeted therapy responsiveness. Moreover, the prognostic role of EGFR expression remains controversial. In the present study, we evaluated the role played by EGFR overexpression in CCRCC and its prognostic significance associated with different immunohistochemical localization patterns. In our study, the Total Score (TS) related to membranous-cytoplasmic EGFR expression showed a significant correlation with grade, pathologic stage (pT), and Stage, Size, Grade, and Necrosis (SSIGN) score, and a negative correlation with nuclear EGFR expression. No significant correlations were shown between nuclear EGFR and clinic-pathological features. Additionally, a correlation between SGLT1 expression levels and pT was described. Multivariate analysis identifies pT and SSIGN score as independent prognostic factors for CCRCC. A significantly increased survival rate was found in the case of positive expression of nuclear EGFR and SGLT1. Based on our findings, SGLT1 and nuclear EGFR overexpression defines a subgroup of CCRCC patients with good prognosis. Membranous-cytoplasmic EGFR expression was shown to be a poor prognostic factor and could define a CCRCC subgroup with poor prognosis that should be responsive to anti-EGFR therapies.

Identifiants

pubmed: 34445451
pii: ijms22168747
doi: 10.3390/ijms22168747
pmc: PMC8395723
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
SLC5A1 protein, human 0
Sodium-Glucose Transporter 1 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fondazione di Sardegna
Organisme : Fondo di Ateneo per la Ricerca 2020 University of sassari
Organisme : Deutsche Forschungsgemeinschaft
ID : RI2695/1-3

Références

Cancer. 2005 Dec 1;104(11):2323-33
pubmed: 16240452
Int J Gynecol Pathol. 1994 Jul;13(3):234-40
pubmed: 7928056
Mod Pathol. 2013 Jan;26(1):106-16
pubmed: 22899295
BJU Int. 2011 Nov;108(10):1556-63
pubmed: 21952069
Metabolites. 2020 Dec 13;10(12):
pubmed: 33322148
J Biol Chem. 2005 Sep 2;280(35):31182-9
pubmed: 16000298
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
J Clin Pathol. 2004 Jul;57(7):773-5
pubmed: 15220376
Am J Cancer Res. 2015 Dec 15;6(1):71-83
pubmed: 27073724
Ann N Y Acad Sci. 2005 Nov;1059:11-5
pubmed: 16382038
Cancer Res. 2005 Jan 1;65(1):338-48
pubmed: 15665312
Mol Carcinog. 2009 Jul;48(7):610-7
pubmed: 19058255
Expert Rev Mol Diagn. 2019 May;19(5):397-407
pubmed: 30983433
J Clin Oncol. 2005 Apr 10;23(11):2445-59
pubmed: 15753456
J Pathol. 1998 Apr;184(4):424-9
pubmed: 9664910
Eur Urol Focus. 2021 Mar 10;:
pubmed: 33714725
Radiother Oncol. 2005 Aug;76(2):157-61
pubmed: 16024112
Cancer. 2012 Mar 1;118(5):1268-75
pubmed: 22161775
Anticancer Res. 2005 May-Jun;25(3B):1901-7
pubmed: 16158924
J Biomed Sci. 2012 Apr 05;19:40
pubmed: 22475688
Cancer Genet Cytogenet. 2001 Mar;125(2):139-46
pubmed: 11369057
Aging (Albany NY). 2018 Dec 11;10(12):3957-3985
pubmed: 30538212
Int J Cancer. 1996 Feb 20;69(1):17-22
pubmed: 8600053
Med Hypotheses. 2015 Aug;85(2):183-5
pubmed: 25959864
Cancer Cell. 2008 May;13(5):385-93
pubmed: 18455122
Urologia. 2019 Feb;86(1):3-8
pubmed: 30270773
Eur Urol. 2011 Oct;60(4):615-21
pubmed: 21741761
Br J Cancer. 2006 Jan 30;94(2):184-8
pubmed: 16434982
Indian J Pathol Microbiol. 2016 Jan-Mar;59(1):35-40
pubmed: 26960632
Clin Cancer Res. 2005 Aug 15;11(16):5856-62
pubmed: 16115926
Urol Oncol. 2009 Sep-Oct;27(5):548-50
pubmed: 18625569
Invest New Drugs. 2003 Feb;21(1):99-101
pubmed: 12795534
Mod Pathol. 2010 Mar;23(3):392-403
pubmed: 20062009
Radiother Oncol. 2013 Sep;108(3):370-7
pubmed: 23830194
Br J Cancer. 1994 Jun;69(6):1120-5
pubmed: 7911031
Am J Clin Oncol. 2010 Dec;33(6):614-8
pubmed: 20142724
Hum Pathol. 1997 Nov;28(11):1255-9
pubmed: 9385930
Int J Clin Oncol. 2011 Oct;16(5):494-9
pubmed: 21431345
Clin Genitourin Cancer. 2007 Mar;5(4):264-70
pubmed: 17553206
Oncotarget. 2017 Dec 8;8(69):113502-113515
pubmed: 29371925
J Urol. 2006 Apr;175(4):1235-9
pubmed: 16515968
Eur Urol Oncol. 2019 Sep;2(5):505-514
pubmed: 31377308
Am J Transl Res. 2009 Mar 08;1(3):249-58
pubmed: 19956435

Auteurs

Maria Rosaria Muroni (MR)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.

Silvia Ribback (S)

Institut fuer Pathologie, Universitaetsmedizin Greifswald, Friedrich-Loeffler-Str. 23e, 17475 Greifswald, Germany.

Giovanni Sotgiu (G)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.

Nils Kroeger (N)

Klinik und Poliklinik fuer Urologie, Universitaetsmedizin Greifswald, Sauerbruchstr, 17475 Greifswald, Germany.

Laura Saderi (L)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.

Andrea Angius (A)

Istituto di Ricerca Genetica e Biomedica (IRGB), CNR, Cittadella Universitaria di Cagliari, 09042 Monserrato, Italy.

Paolo Cossu-Rocca (P)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.
Surgical Pathology Unit, Department of Diagnostic Services, "Giovanni Paolo II" Hospital, ASSL Olbia-ATS Sardegna, 07026 Olbia, Italy.

Maria Rosaria De Miglio (MR)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella, 4, 07100 Sassari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH